Guidelines for the management of hemophilia

Haemophilia

Volumn 19, Issue 1, 2013, Pages

  Srivastava, A ^a   Brewer, A K ^b   Mauser Bunschoten, E P ^c   Key, N S ^d   Kitchen, S ^e   Llinas, A ^f   Ludlam, C A ^g   Mahlangu, J N ^h   Mulder, K ⁱ   Poon, M C ^j   Street, A ^k  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^f HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^g ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^h NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

ⁱ HEALTH SCIENCES CENTRE   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

^k ALFRED HOSPITAL   (Australia)

more..

Author keywords

Bleeding disorders; Guidelines; Hemophilia; Management; Treatment

Indexed keywords

AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CYCLOOXYGENASE 2 INHIBITOR; DESMOPRESSIN; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; TRANEXAMIC ACID;

AGING; AMNIOCENTESIS; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CHORION VILLUS SAMPLING; CRYOPRECIPITATION; DENTAL PROCEDURE; DIABETES MELLITUS; EPISTAXIS; FITNESS; GENETIC COUNSELING; GINGIVA BLEEDING; HEALTH CARE; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIC ARTHROPATHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ILIOPSOAS HEMATOMA; KIDNEY HEMORRHAGE; LABORATORY DIAGNOSIS; MEDICAL PRACTICE; MUSCLE BLEEDING; OBESITY; ORAL BLEEDING; OSTEOPOROSIS; PATIENT CARE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY CONTROL; QUALITY OF LIFE; SEXUALITY; SOCIAL PSYCHOLOGY; SURGERY; SYNOVECTOMY; SYNOVITIS; VON WILLEBRAND DISEASE;

BLOOD COAGULATION FACTORS; COMPREHENSIVE HEALTH CARE; DELIVERY OF HEALTH CARE; HEMOPHILIA A; HEMORRHAGE; HEMOSTATICS; HUMANS; PAIN MANAGEMENT;

EID: 84871011258     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02909.x     Document Type: Article

References (324)

1. Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16: 20-32.
2. Ingram GI, Dykes SR, Creese AL et al. Home treatment in haemophilia: clinical, social and economic advantages. Clin Lab Haematol 1979; 1: 13-27.
3. Singleton T, Kruse-Jarres R, Leissinger C. Emergency department care for patients with haemophilia and von Willebrand disease. J Emerg Med 2010; 39: 158-65.
4. Castaman G, Mancuso ME, Giacomelli SH et al. Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A. J Thromb Haemost 2009; 7: 1824-31.
5. Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A. Blood Coagul Fibrinolysis 2010; 21: 615-9.
6. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia 2000; 6(Suppl. 1): 60-7.
7. Berntorp E, Boulyzenkov V, Brettler D et al. Modern treatment of haemophilia. Bull WHO 1995; 73: 691-701.
8. Kasper CK, Mannucci PM, Boulyzenkov V et al. Haemophilia in the 1990s: principles of treatment and improved access to care. Semin Thrombosis Haemostas 1992; 18: 1-10.
9. Soucie JM, Nuss R, Evatt B et al. Hemophilia Surveillance System Project Investigators. Mortality among males with hemophilia: relations with source of medical care. Blood 2000; 96: 437-42.
10. Colvin BT, Astermark J, Fischer K et al. Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia 2008; 14: 361-74.
11. Evatt BL. The natural evolution of haemophilia care: developing and sustaining comprehensive care globally. Haemophilia 2006; 12(Suppl. 3): 13-21.
12. Evatt BL, Black C, Batorova A, Street A, Srivastava A. Comprehensive care for haemophilia around the world. Haemophilia 2004; 10(Suppl. 4): 9-13.
13. Canadian Hemophilia Standards Group. Canadian Comprehensive Care Standards for Hemophilia and Other Inherited Bleeding Disorders, 1st edn, June 2007. Available at http://www.ahcdc.ca/documents/CanadianHemophiliaStandardsFirstEdition070612_1.pdf. Accessed April 9, 2011.
14. De Moerloose P, Fischer K, Lambert T et al. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. Haemophilia 2012; 18: 319-25.
15. Gomis M, Querol F, Gallach JE, Gonzalez LM, Aznar JA. Exercise and sport in the treatment of haemophilic patients: a systematic review. Haemophilia 2009; 15: 43-54.
16. Iorio A, Fabbriciani G, Marcucci M, Brozzetti M, Filipponi P. Bone mineral density in haemophilia patients: a meta-analysis. Thromb Haemost 2010; 103: 596-603.
17. Wallny TA, Scholz DT, Oldenburg J et al. Osteoporosis in haemophilia - an underestimated comorbidity? Haemophilia 2007; 13: 79-84.
18. Seuser A, Boehm P, Kurme A, Schumpe G, Kurnik K. Orthopaedic issues in sports for persons with haemophilia. Haemophilia 2007; 13(Suppl. 2): 47-52.
19. Philpott J, Houghton K, Luke A. Physical activity recommendations for children with specific chronic health conditions: Juvenile idiopathic arthritis, hemophilia, asthma and cystic fibrosis. Paediatr Child Health 2010; 15: 213-25.
20. Querol F, Aznar JA, Haya S, Cid A. Orthoses in haemophilia. Haemophilia 2002; 8: 407-12.
21. Fischer K, Van der Bom JG, Mauser-Bunschoten EP et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001; 7: 446-52.
22. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients: a long-term follow-up. J Intern Med 1997; 241: 395-400.
23. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
24. Aronstam A, Arblaster PG, Rainsford SG, Turk P, Slattery M, Alderson MR et al. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol 1976; 33: 81-90.
25. Astermark J, Petrini P, Tengborn L et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
26. Feldman BM, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
27. Fischer K, Van der Bom JG, Mauser-Bunschoten EP et al. Effects of postponing prophylactic treatment on long-term outcome in patients with severe haemophilia. Blood 2002; 99: 2337-41.
28. Gringeri A, Lundin B, Mackensen SV et al., ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
29. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. NEJM 2007; 357: 535-44.
30. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001; 7: 99-102.
31. Fischer K, Van Der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 7: 544-50.
32. Hay CR. Prophylaxis in adults with haemophilia. Haemophilia 2007; 13(Suppl. 2): 10-5.
33. Kavakli K, Aydogdu S, Taner M et al. Radioisotope synovectomy with rhenium186 in haemophilic synovitis for elbows, ankles and shoulders. Haemophilia 2008; 14: 518-23.
34. Luchtman-Jones L, Valentino LA, Manno C, Recombinant Therapy Workshop Participants. Considerations in the evaluation of haemophilia patients for short-term prophylactic therapy: a paediatric and adult case study. Haemophilia 2006; 12: 82-6.
35. Petrini P, Seuser A. Haemophilia care in adolescents-compliance and lifestyle issues. Haemophilia 2009; 15(Suppl. 1): 15-9.
36. Soucie JM, Symons J, Evatt B, Brettler D, Huszti H, Linden J, Hemophilia Surveillance System Project Investigators. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 2001; 7: 198-206.
37. Teitel JM, Barnard D, Israels S, Lillicrap D, Poon MC, Sek J. Home management of haemophilia. Haemophilia 2004; 10: 118-33.
38. Szucs TD, Offner A, Kroner B et al. European socioeconomic study group. Resource utilization in haemophiliacs treated in Europe: results from the European study on socioeconomic aspects of haemophilia care. Haemophilia 1998; 4: 498-501.
39. Neunert CE, Miller KL, Journeycake JM et al. Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience. Haemophilia 2008; 14: 260-70.
40. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134-46.
41. Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol 2007; 138: 580-6.
42. Ragni MV, Journeycake JM, Brambilla DJ. Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis. Haemophilia 2008; 14: 30-8.
43. Su Y, Wong WY, Lail A, Donfield SM, Konzal S, Gomperts E, Hemophilia Growth and Development Study. Long-term major joint outcomes in young adults with haemophilia: interim data from the HGDS. Haemophilia 2007; 13(4): 387-90.
44. Hermans C, de Moerloose P, Fischer K, Holstein K, Klamroth R, Lambert T et al. European Haemophilia Therapy Standardisation Board. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia 2011; 17: 383-92.
45. Vallejo L, Pardo A, Gomis M et al. Influence of aquatic training on the motor performance of patients with haemophilic arthropathy. Haemophilia 2010; 16: 155-61.
46. Rattray B, Nugent DJ, Young G. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia 2006; 12: 514-7.
47. Tsoukas C, Eyster ME, Shingo S et al. Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood 2006; 107: 1785-90.
48. Eyster ME, Asaad SM, Gold BD, Cohn SE, Goedert JJ, Second Multicenter Hemophilia Study Group. Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs. Haemophilia 2007; 13: 279-86.
49. Rodriguez-Merchan EC. Musculoskeletal complications of hemophilia. HSSJ 2010; 6: 37-42.
50. Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol 2000; 110: 715-20.
51. Hermans C, Altisent C, Batorova A et al., European Haemophilia Therapy Standardisation Board. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009; 15: 639-58.
52. Mathews V, Viswabandya A, Baidya S et al. Surgery for hemophilia in developing countries. Semin Thromb Hemost 2005; 31: 538-43.
53. Teitel JM, Carcao M, Lillicrap D et al. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009; 15: 227-39.
54. Kempton CL, Soucie JM, Miller CH et al. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost 2010; 8: 2224-31.
55. Eckhardt CL, Van der Bom JG, Van der Naald M, Peters M, Kamphuisen PW, Fijnvandraat K. Surgery and inhibitor development in hemophilia A: a systematic review. J Thromb Haemost 2011; 9: 1948-58.
56. Friedman M, White B, Dougall AJ. An audit of the protocol for the management of patients with hereditary bleeding disorders undergoing dental treatment. J Disab Oral Health 2009; 10: 151-5.
57. Frachon X, Pommereuil M, Berthier AM et al. Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000-2002). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99: 270-5.
58. Hewson I, Makhmalbaf P, Street A et al. Dental surgery with minimal factor support in the inherited bleeding disorder population at the Alfred Hospital. Haemophilia 2011; 17: e185-8.
59. Coetzee MJ. The use of topical crushed tranexamic acid tablets to control bleeding after dental surgery and from skin ulcers in haemophilia. Haemophilia 2007; 13: 443-4.
60. Franchini M, Rossetti G, Tagliaferri A et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia 2005; 11: 504-9.
61. Brewer A. Dental Management of Patients with Inhibitors to Factor VIII or Factor IX. Treatment of Hemophilia monograph no 45. Montreal: World Federation of Hemophilia, 2008.
62. White G, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
63. Aronstam A, Rainsford SG, Painter MJ. Patterns of bleeding in adolescents with severe haemophilia A. Br Med J 1979; 1: 469-70.
64. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. JTH 2012 (in press).
65. Lee CA, Chi C, Pavord SR et al. UK Haemophilia Centre Doctors' Organization. The obstetric and gynaecological management of women with inherited bleeding disorders-review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. Haemophilia 2006; 12: 301-36.
66. Rizza CR, Rhymes IL, Austen DE, Kernoff PB, Aroni SA. Detection of carriers of haemophilia: a 'blind' study. Br J Haematol 1975; 30: 447-56.
67. Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH et al. Bleeding in carriers of hemophilia. Blood 2006; 108: 52-6.
68. Chi C, Lee CA, Shiltagh N, Khan A, Pollard D, Kadir RA. Pregnancy in carriers of hemophilia. Haemophilia 2008; 14: 56-64.
69. Ljung R, Tedgård U. Genetic counseling of hemophilia carriers. Semin Thromb Hemost 2003; 29: 31-6.
70. Dunn NF, Miller R, Griffioen A, Lee CA. Carrier testing in haemophilia A and B: adult carriers' and their partners' experiences and their views on the testing of young females. Haemophilia 2008; 14: 584-92.
71. Mortarino M, Garagiola I, Lotta LA, Siboni SM, Semprini AE, Peyvandi F. Non-invasive tool for foetal sex determination in early gestational age. Haemophilia 2011; 17: 952-6.
72. Rijnders RJ, van der Luijt RB, Peters ED et al. Earliest gestational age for fetal sexing in cell-free maternal plasma. Prenat Diagn 2003; 23: 1042-4.
73. Chi C, Hyett JA, Finning KM, Lee CA, Kadir RA. Non-invasive first trimester determination of fetal gender: a new approach of prenatal diagnosis of haemophilia. BJOG 2006; 113: 239-42.
74. Evans MI, Andriole S. Chorionic villus sampling and amniocentesis in 2008. Curr Opin Obstet Gynecol 2008; 20: 164-8.
75. Jauniaux E, Pahal GS, Rodeck CH. What invasive procedure to use in early pregnancy? Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14: 651-62.
76. Tabor A, Alfirevic Z. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther 2010; 27: 1-7.
77. Wapner RJ. Invasive prenatal diagnostic techniques. Semin Perinatol 2005; 29: 401-4.
78. Katiyar R, Kriplani A, Agarwal N, Bhatla N, Kabra M. Detection of fetomaternal hemorrhage following chorionic villus sampling by Kleihauer Betke test and rise in maternal serum alpha feto protein. Prenat Diagn 2007; 27: 139-42.
79. Lavery S. Preimplantation genetic diagnosis of haemophilia. Br.J Haematol 2009; 144: 303-7.
80. Kletzel M, Miller CH, Becton DL, Chadduck WM, Elser JM. Postdelivery head bleeding in hemophilic neonates: causes and management. Am J Dis Child 1989; 143: 1107-10.
81. Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. Br J Haematol 2001; 112: 264-74.
82. Evans DI, Shaw A. Safety of intramuscular injection of hepatitis B vaccine in haemophiliacs. BMJ 1990; 300: 1694-5.
83. Miller EJ, Lee CA, Karayiannis P, Holmes S, Thomas HC, Kernoff PB. Immune response of patients with congenital coagulation disorders to hepatitis B vaccine: suboptimal response and human immunodeficiency virus infection. J Med Virol 1989; 28: 96-100.
84. Steele M, Cochrane A, Wakefield C et al. Hepatitis A and B immunization for individuals with inherited bleeding disorders. Haemophilia 2009; 15: 437-47.
85. Cassis F. Psychosocial Care for People with Hemophilia. Treatment of Hemophilia monograph no 44. Montreal: World Federation of Hemophilia, 2007.
86. Miller R. Counselling about diagnosis and inheritance of genetic bleeding disorders: haemophilia A and B. Haemophilia 1999; 5: 77-83.
87. Bullinger M, von Mackensen S. Psychosocial determinants of quality of life in children and adolescents with haemophilia: a cross-cultural approach. Clin Psychol Psychother 2008; 15: 164-72.
88. Mauser-Bunschoten EP, Fransen Van De Putte DE, Schutgens RE. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 2009; 15: 853-63.
89. Siboni SM, Mannucci PM, Gringeri A et al. Health status and quality of life of elderly persons with severe haemophilia born before the advent of modern replacement therapy. J Thromb Haemost 2009; 7: 780-6.
90. Iorio A, Fabbriciani G, Marcucci M, Brozzetti M, Filipponi P. Bone mineral density in haemophilia patients: a meta-analysis. Thromb Haemost 2010; 103: 596-603.
91. Wallny TA, Scholz DT, Oldenburg J et al. Osteoporosis in haemophilia - an underestimated comorbidity? Haemophilia 2007; 13: 79-84.
92. Kovacs CS. Hemophilia, low bone mass, and osteopenia/osteoporosis. Transfus Apher Sci 2008; 38: 33-40.
93. Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients Prescribed Bisphosphonates: Dental Clinical Guidance. Scottish Dental Clinical Effectiveness Programme, Dundee, 2011.
94. Hofstede FG, Fijnvandraat K, Plug I, Kamphuisen PW, Rosendaal FR, Peters M. Obesity: a new disaster for haemophilic patients? A nationwide survey Haemophilia 2008; 14: 1035-8.
95. Soucie JM, Cianfrini C, Janco RL et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103: 2467-73.
96. Carpenter SL, Chrisco M, Johnson E. The effect of overweight and obesity on joint damage in patients with moderate to severe hemophilia. Blood 2006; 108: 4064. ASH Annual Meeting Abstracts.
97. Biere-Rafi S, Baarslag MA, Peters M et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost 2011; 105: 274-8.
98. Lim MY, Pruthi RK. Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients. Blood Coagul Fibrinolysis 2011; 22: 402-6.
99. Walsh M, Macgregor D, Stuckless S, Barrett B, Kawaja M, Scully MF. Health-related quality of life in a cohort of adult patients with mild hemophilia A. J Thromb Haemost 2008; 6: 755-61.
100. Rosendaal FR, Briet E, Stibbe J et al. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990; 75: 525-30.
101. Kulkarni R, Soucie JM, Evatt BL, Hemophilia Surveillance System Project Investigators. Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol 2005; 79: 36-42.
102. Ragni MV, Moore CG. Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A. Haemophilia 2011; 17: 867-71.
103. Girolami A, Ruzzon E, Fabris F, Varvarikis C, Sartori R, Girolami B. Myocardial infarction and other arterial occlusions in hemophilia A patients: a cardiological evaluation of all 42 cases reported in the literature. Acta Haematol 2006; 116: 120-5.
104. Schutgens RE, Tuinenburg A, Roosendaal G, Guyomi SH, Mauser-Bunschoten EP. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia 2009; 15: 952-8.
105. Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly patients with hemophilia. Blood 2009; 114: 5256-63.
106. Tuinenburg A, Mauser-Bunschoten EP, Verhaar MC, Biesma DH, Schutgens RE. Cardiovascular disease in patients with hemophilia. J Thromb Haemost 2009; 7: 247-54.
107. Coppola A, Tagliaferri A, Franchini M. The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost 2010; 36: 91-102.
108. Street A, Hill K, Sussex B, Warner M, Scully MF. Haemophilia and ageing. Haemophilia 2006; 12(Suppl. 3): 8-12.
109. Kitchen S, McCraw A, Echenagucia M. Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory Manual, 2nd edn. Montreal: World Federation of Hemophilia, 2010.
110. Clinical and Laboratory Standards Institute. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays: Approved Guideline, 5th edn. CLSI H21-A5, Wayne, PA; Clinical and Laboratory Standards Institute, 2008.
111. Woodhams B, Girardot O, Blanco MJ et al. Stability of coagulation proteins in frozen plasma. Blood Coagul Fibrinolysis 2001; 12: 229-36.
112. Clinical and Laboratory Standards Institute. One Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test: Approved Guideline-Second edition. CLSI H47-A2. Wayne, PA; Clinical and Laboratory Standards Institute, 2008.
113. Bick RL. Laboratory evaluation of platelet dysfunction. Clin Lab Med 1995; 15: 1-38.
114. Rodgers RP, Levin J. Bleeding time revisited. Blood 1992; 1: 79.
115. Duncan EM, Duncan BM, Tunbridge LJ et al. Familial discrepancy between one stage and 2 stage factor VIII assay methods in a subgroup of patients with haemophilia A. Br J Haematol 1994; 87: 846-8.
116. Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic FVIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Haemostaseologie 2010; 30: 207-11.
117. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost 2009; 35: 786-93.
118. Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen. Semin Thromb Hemost 2009; 35: 752-9.
119. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemos 1995; 73: 247-51.
120. Clinical and Laboratory Standards Institute. Protocol for the Evaluation, Validation, and Implementation of Coagulometers: Approved Guideline. CLSI document H57-A, Vol.28 No.4. Wayne, PA; Clinical and Laboratory Standards Institute, 2008.
121. Gardiner C, Kitchen S, Dauer RJ et al. Recommendations for evaluation of coagulation analyzers. Lab Hematol 2006; 12: 32-8.
122. Jennings I, Kitchen DP, Woods TA et al. Laboratory performance in the World Federation of Hemophilia EQA programme, 2003-2008. Haemophilia 2009; 15: 571-7.
123. Evatt BL, Austin H, Leon G, Ruiz-Sáez A, de Bosch N. Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate. Haemophilia 1999; 5: 295-300.
124. Farrugia A. Guide for the Assessment of Clotting Factor Concentrates, 2nd edn. Montreal: World Federation of Hemophilia, 2008.
125. Brooker M. Registry of Clotting Factor Concentrates, 9th edn. Facts and Figures monograph no 6. Montreal: World Federation of Hemophilia, 2012.
126. Brettler DB, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan JL. Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies. Blood 1989; 15: 73.
127. Recht M, Pollmann H, Tagliaferri A, Musso R, Janco R, Neuman WR. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011; 17: 494-9.
128. Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med 2007; 39: 346-58.
129. Kim HC, McMillan CW, White GC et al. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-75.
130. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 2008; 34: 747-61.
131. Giangrande PL. Blood products for hemophilia: past, present and future. BioDrugs 2004; 18: 225-34.
132. Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003; 9: 24-37.
133. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
134. Hemophilia of Georgia. Protocols for the Treatment of Hemophilia and Von Willebrand Disease, February 2012. Available at http://www.hog.org/docLib/20090820_HoGProtocol2009.pdf (Accessed June 6, 2012).
135. Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol 2000; 110: 715-20.
136. Martinowitz U, Luboshitz J, Bashari D et al. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia. Haemophilia 2009; 15: 676-85.
137. Martinowitz U, Schulman S, Gitel S et al. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992; 82: 729-34.
138. Mathews V, Viswabandya A, Baidya S et al. Surgery for hemophilia in developing countries. Semin Thromb Hemost 2005; 31: 538-43.
139. Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant FIX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thrombosis and Hemostasis 2002; 87: 431-5.
140. Ruiz-Sáez A, Hong A, Arguello A et al. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate. Haemophilia 2005; 11: 583-8.
141. Shibata M, Shima M, Misu H et al. Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia 2003; 9: 269-71.
142. Chamberland ME. Surveillance for transfusion-transmitted viral infections in the United States. Biologicals 1998; 26: 85-8.
143. O'Shaughnesy DF, Atterbury C, Bolton Maggs P et al. Guideline for the use of fresh frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11-28.
144. Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology Am Soc Hematol Educ Program 2007; 00: 179-86.
145. Kasper CK. Products for clotting factor replacement in developing countries. Semin Thromb Hemost 2005; 31: 507-12.
146. Budde U, Drewke E. Von Willebrand factor multimers in virus-inactivated plasmas and F VIII concentrates. Beitr Infusionsther Transfusionsmed 1994; 32: 408-14.
147. Chin S, Williams B, Gottlieb P et al. Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants. Blood 1995; 86: 4331-6.
148. Chuansumrit A, Isarangkura P, Chantanakajornfung A et al. The efficacy and safety of lyophilized cryoprecipitate in hemophilia A. J Med Assoc Thai 1999; 82(Suppl. 1): S69-73.
149. El-Ekiaby M, Sayed MA, Caron C et al. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med 2010; 20: 48-61.
150. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-21.
151. Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A. Blood Coagul Fibrinolysis 2010; 21: 615-9.
152. Leissinger C, Becton D, Cornell C Jr, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001; 7: 258-66.
153. Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood 2005; 105: 3382.
154. Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A Systematic Review: the use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia 2012; 18: 25-33.
155. Castaman G. Desmopressin for the treatment of haemophilia. Haemophilia 2008; 14(Suppl. 1): 15-20.
156. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82: 87-93.
157. Khair K, Baker K, Mathias M et al. Intranasal desmopressin (Octim): a safe and efficacious treatment option for children with bleeding disorders. Haemophilia 2007; 13: 548-51.
158. Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991; 114: 563-8.
159. Sica DA, Gehr TWG. Desmopressin: safety considerations in patients with chronic renal disease. Drug Saf 2006; 29: 553-6.
160. Das P, Carcao M, Hitzler J. DDAVP-induced hyponatremia in young children. J Pediatr Hematol Oncol 2005; 27: 330-2.
161. Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31: 199-202.
162. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 4: 245-53.
163. Coetzee MJ. The use of topical crushed tranexamic acid tablets to control bleeding after dental surgery and from skin ulcers in haemophilia. Haemophilia 2007; 13: 443-4.
164. Frachon X, Pommereuil M, Berthier AM et al. Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000-2002). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99: 270-5.
165. Kouides PA, Byams VR, Philipp CS et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009; 145: 212-20.
166. Franchini M, Rossetti G, Tagliaferri A et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia 2005; 11: 504-9.
167. Hvas AM, Sorensen HT, Norengaard L et al. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007; 5: 2408-14.
168. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10(Suppl. 2): 10-6.
169. Giangrande PL, Wilde JT, Madan B et al. Consensus protocol for the use of recombinant activated factor VII in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 2009; 15: 501-8.
170. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. JTH 2012 (in press).
171. Aronstam A, Wassef M, Choudhury DP, Turk PM, McLellan DS. Double-blind controlled trial of three dosage regimens in treatment of haemarthroses in haemophilia A. Lancet 1980; 26: 1.
172. Aronstam A, Wassef M, Hamad Z, Cartlidge J, McLellan D. A double-blind controlled trial of two dose levels of factor VIII in the treatment of high risk haemarthroses in haemophilia A. Clin Lab Haematol 1983; 5: 157-63.
173. Hermans C, de Moerloose P, Fischer K, Holstein K, Klamroth R, Lambert T et al., European Haemophilia Therapy Standardisation Board. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia 2011; 17: 383-92.
174. Mathews V, Viswabandya A, Baidya S et al. Surgery for hemophilia in developing countries. Semin Thromb Hemost 2005; 31: 538-43.
175. Gomis M, Querol F, Gallach JE, Gonzalez LM, Aznar JA. Exercise and sport in the treatment of haemophilic patients: a systematic review. Haemophilia 2009; 15: 43-54.
176. Mulder K. Exercises for People with Hemophilia. Montreal: World Federation of Hemophilia, 2006.
177. Heijnen L, Buzzard BB. The role of physical therapy and rehabilitation in the management of hemophilia in developing countries. Semin Thromb Hemost 2005; 31: 513-7.
178. Ingram GI, Mathews JA, Bennett AE. Controlled trial of joint aspiration in acute haemophilic haemarthrosis. Ann Rheum Dis 1972; 31: 423.
179. Rodriguez-Merchan EC. Aspects of current management: orthopaedic surgery in haemophilia. Haemophilia 2012; 18: 8-16.
180. Aronstam A, Browne RS, Wassef M, Hamad Z. The clinical features of early bleeding into the muscles of the lower limb in severe haemophiliacs. J Bone Joint Surgery 1983; 65-B: 19-23.
181. Beyer R, Ingerslev J, Sørensen B. Current practice in the management of muscle haematomas in patients with severe haemophilia. Haemophilia 2010; 16: 926-31.
182. Railton GT, Aronstam A. Early bleeding into upper limb muscles in severe haemophilia clinical features and treatment. J Bone Joint Surgery 1987; 69-B: 100-2.
183. Rodriguez-Merchan EC. Musculoskeletal complications of hemophilia. HSSJ 2010; 6: 37-42.
184. Singleton T, Kruse-Jarres R, Leissinger C. Emergency department care for patients with hemophilia and von Willebrand disease. J Emerg Med 2010; 39: 158-65.
185. Llinás A, Silva M, Pasta G, Luck JV et al. Controversial subjects in musculoskeletal care of haemophilia: cross fire. Haemophilia 2010; 16(Suppl. 5): 132-5.
186. Rodriguez-Merchan EC. Orthopedic management in hemophilia: a Spanish outlook. Semin Hematol 2008; 45(2 Suppl. 1): S58-63.
187. Blamey G, Forsyth A, Zourikian N et al. Comprehensive elements of a physiotherapy exercise programme in haemophilia-a global perspective. Haemophilia 2010; 16(Suppl. 5): 136-45.
188. Beeton K, Cornwell J, Alltree J. Rehabilitation of Muscle Dysfunction in Hemophilia, 2nd edn. World Federation of Hemophilia Treatment of Hemophlia monograph 24. Montreal: World Federation of Hemophilia, 2012.
189. Ashrani AA, Osip J, Christie B, Key NS. Iliopsoas haemorrhage in patients with bleeding disorders-experience from one centre. Haemophilia 2003; 9: 721-6.
190. Balkan C, Kavakli K, Karapinar D. Iliopsoas haemorrhage in patients with haemophilia: results from one centre. Haemophilia 2005; 11: 463-7.
191. Fernandez-Palazzi F, Hernandez SR, De Bosch NB, De Saez AR. Hematomas within the iliopsoas muscles in hemophilic patients: the Latin American experience. Clin Orthop Relat Res 1996; 328: 19-24.
192. Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol 2008; 140: 378-84.
193. Nakar C, Cooper DL, DiMichele D. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008). Haemophilia 2010; 16: 625-31.
194. Patiroglu T, Ozdemir MA, Unal E et al. Intracranial hemorrhage in children with congenital factor deficiencies. Childs Nerv Syst 2011; 27: 1963-6.
195. Zanon E, Iorio A, Rocino A et al. the Italian Association of Hemophilia Centers. Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia 2012; 18: 39-45.
196. Traivaree C, Blanchette V, Armstrong D et al. Intracranial bleeding in haemophilia beyond the neonatal period-the role of CT imageing in suspected intracranial bleeding. Haemophilia 2007; 13: 552-9.
197. Witmer CM, Manno CS, Butler RB, Raffini LJ. The clinical management of hemophilia and head trauma: a survey of current clinical practice among pediatric hematology/oncology physicians. Pediatr Blood Cancer 2009; 53: 406-10.
198. Bush MT, Roy N. Hemophilia emergencies. J Emerg Nurs 1995; 21: 531-8.
199. Guthrie TH Jr, Sacra JC. Emergency care of the hemophiliac patient. Ann Emerg Med 1980; 9: 476-9.
200. Kouides PA, Fogarty PF. How do we treat upper gastrointestinal bleeding in adults with haemophilia. Haemophilia 2010; 16: 360-2.
201. Mittal R, Spero JA, Lewis JH et al. Patterns of gastrointestinal hemorrhage in hemophilia. Gastroenterology 1985; 88: 515-22.
202. Quon DV, Konkle BA. How we treat haematuria in adults with haemophilia. Haemophilia 2010; 16: 683-5.
203. Ghosh K, Jijina F, Mohanty D. Haematuria and urolithiasis in patients with haemophilia. Eur J Haematol 2003; 70: 410-2.
204. Kane MJ, Silverman LR, Rand JH, Paciucci PA, Holland JF. Myonecrosis as a complication of the use of epsilon amino-caproic acid: a case report and review of the literature. Am J Med 1988; 85: 861-3.
205. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 23: 339.
206. Franchini M, Rossetti G, Tagliaferri A et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia 2005; 11: 504-9.
207. Vinall C, Stassen LF. The dental patient with a congenital bleeding disorder. J Ir Dent Assoc 2008; 54: 24-8.
208. d'Young AI. Domiciliary application of CryoCuff in severe haemophilia: qualitative questionnaire and clinical audit. Haemophilia 2008; 14: 823-7.
209. Llinás A. Haemophilic arthropathy. Haemophilia 2010; 16(Suppl. 5): 121.
210. Rodriguez-Merchan EC. Musculoskeletal complications of hemophilia. HSSJ 2010; 6: 37-42.
211. Rodriguez-Merchan EC. Aspects of current management: orthopaedic surgery in haemophilia. Haemophilia 2012; 18: 8-16.
212. Seuser A, Berdel P, Oldenburg J. Rehabilitation of synovitis in patients with haemophilia. Haemophilia 2007; 13(Suppl. 3): 26-31.
213. Aronstam A, Arblaster PG, Rainsford SG, Turk P, Slattery M, Alderson MR et al. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol 1976; 33: 81-90.
214. Feldman BM, Pai M, Rivard GE, Israels S et al., Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006;4:1228-36.
215. Gringeri A, Lundin B, Mackensen SV et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
216. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
217. Blamey G, Forsyth A, Zourikian N et al. Comprehensive elements of a physiotherapy exercise programme in haemophilia - a global perspective. Haemophilia 2010; 16(Suppl. 5): 136-45.
218. Gomis M, Querol F, Gallach JE, Gonzalez LM, Aznar JA. Exercise and sport in the treatment of haemophilic patients: a systematic review. Haemophilia 2009; 15: 43-54.
219. Watson T. Current concepts in electrotherapy. Haemophilia 2002; 8: 413-8.
220. De Kleijn P, Gilbert M, Roosendaal G, Poonnose PM, Narayan PM, Tahir N. Functional recovery after bleeding episodes in haemophilia. Haemophilia 2004; 10: 157-60.
221. Rattray B, Nugent DJ, Young G. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia 2006; 12: 514-7.
222. Tsoukas C, Eyster ME, Shingo S et al. Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood 2006; 107: 1785-90.
223. Querol F, Aznar JA, Haya S, Cid A. Orthoses in haemophilia. Haemophilia 2002; 8: 407-12.
224. Llinás A. The role of synovectomy in the management of a target joint. Haemophilia 2008; 14(Suppl. 3): 177-80.
225. Yoon KH, Bae DK, Kim HS, Song SJ. Arthroscopic synovectomy in haemophilic arthropathy of the knee. Int Orthop 2005; 29: 296-300.
226. Thomas S, Gabriel MB, Assi PE, Barboza M, Perri ML, Land MG et al. Radioactive synovectomy with Yttrium90 citrate in haemophilic synovitis: Brazilian experience. Haemophilia 2011; 17: e211-6.
227. Van Kasteren ME, Nováková IR, Boerbooms AM, Lemmens JA. Long term follow up of radiosynovectomy with yttrium-90 silicate in haemophilic haemarthrosis. Ann Rheum Dis 1993; 52: 548-50.
228. Bernal-Lagunas R, Aguilera-Soriano JL, Berges-Garcia A, Luna-Pizarro D, Perez-Hernandez E. Haemophilic arthropathy: the usefulness of intra-articular oxytetracycline (synoviorthesis) in the treatment of chronic synovitis in children. Haemophilia 2011; 17: 296-9.
229. Caviglia HA, Fernandez-Palazzi F, Galatro G, Perez-Bianco R. Chemical synoviorthesis with rifampicin in haemophilia. Haemophilia 2001; 7(Suppl. 2): 26-30.
230. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977; 59: 287-305.
231. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149: 153-9.
232. Doria AS, Lundin B, Miller S et al. Expert Imageing Working Group of The International Prophylaxis Study Group. Reliability and construct validity of the compatible MRI scoring system for evaluation of elbows in haemophilic children. Haemophilia 2008; 14: 303-14.
233. Keshava S, Gibikote S, Mohanta A, Doria AS. Refinement of a sonographic protocol for assessment of haemophilic arthropathy. Haemophilia 2009; 15: 1168-71.
234. Zukotynski K, Jarrin J, Babyn PS et al. Sonography for assessment of haemophilic arthropathy in children: a systematic protocol. Haemophilia 2007; 13: 293-304.
235. Solimeno L, Goddard N, Pasta G et al. Management of arthrofibrosis in haemophilic arthropathy. Haemophilia 2010; 16(Suppl. 5): 115-20.
236. Fernandez-Palazzi F, Battistella LR. Non-operative treatment of flexion contracture of the knee in haemophilia. Haemophilia 1999; 5(Suppl. 1): 20-4.
237. Gilbert MS, Radomisli TE. Management of fixed flexion contracture of the elbow in haemophilia. Haemophilia 1999; 5(Suppl. 1): 39-42.
238. Spilsbury M. Models for psychosocial services in the developed and developing world. Haemophilia 2004; 10(Suppl. 4): 25-9.
239. Wiedel JD. Arthroscopic synovectomy: state of the art. Haemophilia 2002; 8: 372-4.
240. Goddard NJ, Mann HA, Lee CA. Total knee replacement in patients with end-stage haemophilic arthropathy: 25-year results. J Bone Joint Surg Br 2010; 92: 1085-9.
241. Silva M, Luck JV Jr. Radial head excision and synovectomy in patients with hemophilia. Surgical technique. J Bone Joint Surg Am 2008; 90(Suppl. 2 Pt 2): 254-61.
242. Barg A, Elsner A, Hefti D, Hintermann B. Haemophilic arthropathy of the ankle treated by total ankle replacement: a case series. Haemophilia 2010; 16: 647-55.
243. Tsailas PG, Wiedel JD. Arthrodesis of the ankle and subtalar joints in patients with haemophilic arthropathy. Haemophilia 2010; 16: 822-31.
244. Hermans C, Altisent C, Batorova A et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009; 15: 639-58.
245. Lobet S, Pendeville E, Dalzell R et al. The role of physiotherapy after total knee arthroplasty in patients with haemophilia. Haemophilia 2008; 14: 989-98.
246. Mathews V, Viswabandya A, Baidya S et al. Surgery for hemophilia in developing countries. Semin Thromb Hemost 2005; 31: 538-43.
247. De Kleijn P, Blamey G, Zourikian N, Dalzell R, Lobet S. Physiotherapy following elective orthopaedic procedures. Haemophilia 2006; 12(Suppl. 3): 108-12.
248. Heijnen L, Buzzard BB. The role of physical therapy and rehabilitation in the management of hemophilia in developing countries. Semin Thromb Hemost 2005; 31: 513-7.
249. Hermans C, de Moerloose P, Fischer K et al. European Haemophilia Therapy Standardisation Board. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia 2011; 17: 383-92.
250. D'Young AI. Conservative physiotherapeutic management of chronic haematomata and haemophilic pseudotumours: case study and comparison to historical management. Haemophilia 2009; 15: 253-60.
251. Rodriguez-Merchan EC. The haemophilic pseudotumour. Int Orthop 1995; 19: 255-60.
252. Alcalay M, Deplas A. Rheumatological management of patients with hemophilia. Part II: muscle hematomas and pseudotumors. Joint Bone Spine 2002; 69: 556-9.
253. Espandar R, Heidari P, Rodriguez-Merchan EC. Management of haemophilic pseudotumours with special emphasis on radiotherapy and arterial embolization. Haemophilia 2009; 15: 448-57.
254. Rodriguez-Merchan EC. Bone fractures in the haemophilia patient. Haemophilia 2002; 8: 104-11.
255. Lee VN, Srivastava A, Nithyananth M, Kumar P, Cherian VM, Viswabandya A et al. Fracture neck of femur in haemophilia A - experience from a cohort of 11 patients from a tertiary centre in India. Haemophilia 2007; 13: 391-4.
256. Mortazavi SM, Heidari P. Retrograde intramedullary nailing of supracondylar femoral fractures in haemophilic patients. Haemophilia 2008; 14: 661-4.
257. Lee VN, Srivastava A, PalaniKumar C et al. External fixators in haemophilia. Haemophilia 2004; 10: 52-7.
258. Schild FJ, Mauser-Bunschoten EP, Verbout AJ, Van Rinsum AC, Roosendaal G. Total knee arthroplasty in hemophilic arthropathy: efficiency of clotting factor usage in multijoint procedures. J Thromb Haemost 2009; 7: 1741-3.
259. Kavakli K. Fibrin glue and clinical impact on haemophilia care. Haemophilia 1999; 5: 392-6.
260. Serban M, Poenaru D, Pop L, Schramm W et al. Surgery-a challenge in haemophiliacs with inhibitors. Hamostaseologie 2009; 29(Suppl. 1): S39-41.
261. Astermark J, Altisent C, Batorova A et al., European Haemophilia Therapy Standardisation Board. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010; 16: 747-66.
262. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
263. Eckhardt CL, Menke LA, Van Ommen CH et al. Intensive peri-operative use of factor VIII and the Arg593 ->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009; 7: 930-7.
264. Kempton CL, Soucie JM et al. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. JTH 2010; 8: 2224-31.
265. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558-63.
266. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 24: 361.
267. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost 2009; 35: 786-93.
268. Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen. Semin Thromb Hemost 2009; 35: 752-9.
269. de Moerloose P, Fischer K, Lambert T et al. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. Haemophilia 2012; 18: 319-25.
270. Berntorp E, Collins P, D'Oiron R et al. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition. Haemophilia 2011; 17: e202-10.
271. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
272. McMillan CW, Shapiro SS, Whitehurst D et al. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8.
273. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
274. Teitel JM, Carcao M, Lillicrap D et al. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009; 15: 227-39.
275. Colvin BT, Astermark J, Fischer K et al. Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia 2008; 14: 361-74.
276. Teitel JM, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
277. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA Novoseven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
278. Berntorp E, Shapiro A, Astermark J et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006; 12(Suppl. 6): 1-7.
279. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15: 1027-31.
280. Recht M, Pollmann H, Tagliaferri A et al. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011; 17: 494-9.
281. Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-28.
282. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
283. DiMichele DM. Immune tolerance induction in haemophilia: evidence and the way forward. J Thromb Haemost 2011; 9(Suppl. 1): 216-25.
284. Hay CR, Dimichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
285. Beutel K, Hauch H, Rischewski J, Kordes U, Schneppenheim J, Schneppenheim R. ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor. Hamostaseologie 2009; 29: 155-7.
286. Arnold DM, Julian JA, Walker IR et al., Association of Hemophilia Clinic Directors of Canada. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood 2006; 108: 460-4.
287. Lee CA, Sabin CA et al. Morbidity and mortality from transfusion-transmitted disease in haemophilia. Lancet 1995; 345: 1309.
288. Farrugia A, Evers T, Falcou PF, Burnouf T, Amorim L, Thomas S. Plasma fractionation issues. Biologicals 2009; 37: 88-93.
289. Mauser-Bunschoten EP, Posthouwer D, Fischer K, van den Berg HM. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Haemophilia 2007; 13: 697-700.
290. Ludlam CA, Mannucci PM, Powderly WG, European Interdisciplinary Working Group. Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group. Haemophilia 2005; 11: 433-7.
291. Farrugia A, Manno CS, Evatt BL. Emerging and receding risks of therapeutic regimens for haemophilia. Haemophilia 2004; 10(Suppl. 4): 47-54.
292. Tapper ML. Emerging viral diseases and infectious disease risks. Haemophilia 2006; 12(Suppl. 1): 3-7.
293. Evatt BL, Austin H, Leon G, Ruiz-Sáez A, de Bosch N. Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate. Haemophilia 1999; 5: 295-300.
294. Mannucci PM, Gringeri A, Savidge G et al., European-Australian Haemophilia Collaborative Study Group. Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. Br J Haematol 1994; 86: 174-9.
295. Ragni MV, Amato DA, LoFaro ML et al. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. Blood 1995; 85: 2337-46.
296. Humphreys EH, Chang LW, Harris J. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst Rev 2010; 16: CD006517.
297. Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev 2010; CD008740.
298. Spaulding A, Rutherford GW, Siegfried N. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev 2010; 8: CD008651.
299. Denholm JT, Wright EJ, Street A, Sasadeusz JJ. HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection. Haemophilia 2009; 15: 538-43.
300. Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother 2008; 61: 1191-200.
301. Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011; 15: i-xii. 1-210.
302. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 8: 12-22.
303. Posthouwer D, Mauser-Bunschoten EP, Fischer K, Makris M. Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature. Haemophilia 2006; 12: 473-8.
304. Schulze Zur Wiesch J, Pieper D et al. Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Clin Infect Dis 2009; 49: 466-72.
305. Lok AS, Gardiner DF, Lawitz E et al. Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. NEJM 2012; 366: 216-24.
306. Santagostino E, Colombo M, Rivi M et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003; 102: 78-82.
307. Steele M, Cochrane A, Wakefield C, Stain AM, Ling S, Blanchette V et al. Hepatitis A and B immunization for individuals with inherited bleeding disorders. Haemophilia 2009; 15: 437-47.
308. Miller EJ, Lee CA, Karayiannis P, Holmes S, Thomas HC, Kernoff PB. Immune response of patients with congenital coagulation disorders to hepatitis B vaccine: suboptimal response and human immunodeficiency virus infection. J Med Virol 1989; 28: 96-100.
309. Pillay D, Pereira C, Sabin C, Powell L, Zuckerman AJ, Lee CA. A long-term follow-up of hepatitis B vaccination in patients with congenital clotting disorders. Vaccine 1994; 12: 978-83.
310. Mannucci PM, Gringeri A, Morfini M et al. Immunogenicity of a recombinant hepatitis B vaccine in hemophiliacs. Am J Hematol 1988; 29: 211-4.
311. Buehrer JL, Weber DJ, Meyer AA et al. Wound infection rates after invasive procedures in HIV-1 seropositive versus HIV-1 seronegative hemophiliacs. Ann Surg 1990; 211: 492-8.
312. Monch H, Kostering H, Schuff-Werner P et al. Hemophilia A, idiopathic thrombocytopenia and HTLV-III-infection impressive remission after splenectomy: a case report. Onkologie 1986; 9: 239-40.
313. Trieb K, Panotopoulos J, Wanivenhaus A. Risk of infection after total knee arthroplasty in HIV-positive hemophilic patients. J Bone Joint Surg Am 2003; 85-A: 969-70.
314. Ashrani AA, Key NS, Soucie JM, Duffy N, Forsyth A, Geraghty S, Universal Data Collection Project Investigators. Septic arthritis in males with haemophilia. Haemophilia 2008; 14: 494-503.
315. Zuber TJ. Knee joint aspiration and injection. Am Fam Physician 2002; 66: 1497-500.
316. Tourbaf KD, Bettigole RE, Southard SA. Infection in hemophilia. Local bleeding and prophylactic treatment. NY State J Med 1976; 76: 2034-6.
317. Heyworth BE, Su EP, Figgie MP, Acharya SS, Sculco TP. Orthopedic management of hemophilia. Am J Orthop 2005; 34: 479-86.
318. Rodriguez-Merchan EC. Orthopaedic surgery of haemophilia in the 21st century: an overview. Haemophilia 2002b; 8: 360-8.
319. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
320. Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia 2010; 16(Suppl. 5): 181-8.
321. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011c; 9: 700-10.
322. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001c; 7: 446-52.
323. Wu R, Luke KH, Poon MC et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia 2011; 17: 70-4.
324. Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1995; 1(Suppl. 1): 8-13.